1-4 of 4
Jolene Shorr
Close
Sort by
Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2010) 116 (21): 459.
https://doi.org/10.1182/blood.V116.21.459.459
Published: 2010
Journal Articles

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Animesh D. Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2009) 114 (22): 755.
https://doi.org/10.1182/blood.V114.22.755.755
Published: 2009
Journal Articles

TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFRA in Vitro

Jaya Kittur, MD, Terra L Lasho, MT(ASCP), Joseph H Butterfield, MD, Jolene Shorr, Ayalew Tefferi, MD, Animesh D. Pardanani, MBBS, PhD
Journal: Blood
Blood (2008) 112 (11): 2807.
https://doi.org/10.1182/blood.V112.11.2807.2807
Published: 2008
Journal Articles

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard M. Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 97.
https://doi.org/10.1182/blood.V112.11.97.97
Published: 2008